⌘K

16:02:00·416d

PRReleasevia Quantisnow

Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

ByQuantisnow·Wall Street's wire, on your screen.

DRTS· Alpha Tau Medical Ltd.

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

DRTS
Alpha Tau Medical Ltd.
Health Care

Recent analyst ratings

Mar 4UpdatePiper Sandler$5.00
Dec 15UpdateCitigroup$8.00
Apr 24UpdateH.C. Wainwright$9.00
Apr 14UpdateCantor Fitzgerald$20.00
Apr 8UpdatePiper Sandler$19.00
Apr 4UpdateCitigroup$21.00

Related

SEC4d
SEC Form F-3 filed by Alpha Tau Medical Ltd.
PR5d
Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
SEC5d
SEC Form 6-K filed by Alpha Tau Medical Ltd.
SEC9d
SEC Form 6-K filed by Alpha Tau Medical Ltd.
PR9d
Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
PR9d
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
SEC32d
SEC Form 6-K filed by Alpha Tau Medical Ltd.
PR32d
Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026